Accessibility Menu

Braveheart Bio(NASDAQ) BRVE

Market Cap$2.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+66%
5 YearN/A
1 YearN/A
1 MonthN/A
$30.00
+66.67%
+12.00Today
After hours$29.20-$0.80 (-2.67%)
Braveheart Bio last closing stock price
MetricPriceDate
Last closeUSD 29.802026-08-06
Braveheart Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
Since inception+65.56%USD 18.002026-08-04

Braveheart Bio Financials at a Glance

Market Cap

$2.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$14.38

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$30.00

Volume

1,427

Open

$30.20

Previous Close

$29.80

Daily Range

$29.42 - $31.56

52-Week Range

$18.00 - $31.56

Estimated Earnings Date

N/A

BRVE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Braveheart Bio

Braveheart Bio, Inc. is a biotechnology company focused on developing therapeutics for hypertrophic cardiomyopathy. The company’s lead product candidate, BHB-1839, is a small-molecule cardiac myosin inhibitor designed to address this serious heart condition.

Products and Services
  • BHB-1839: A small-molecule cardiac myosin inhibitor
  • Research and development of innovative therapeutics
  • Focus on hypertrophic cardiomyopathy treatment
Growth Outlook
  • Market potential for hypertrophic cardiomyopathy therapeutics is significant
  • Strong pipeline development expected to drive future growth
  • Strategic partnerships may enhance research capabilities
Financial Highlights
  • Market capitalization of approximately $2.15 billion
  • Stock price range between $30.2 and $31.55 over the past year
  • Recent trading volume of 811,959 shares indicates strong investor interest
Braveheart Bio, Inc. is positioned in a niche market with a focus on a critical health issue. The company’s innovative approach to treating hypertrophic cardiomyopathy through BHB-1839 could lead to significant advancements in patient care. With a robust market capitalization and a solid stock price range, Braveheart Bio is attracting attention from investors. The ongoing development of its product pipeline and potential strategic partnerships may further enhance its growth trajectory, making it a noteworthy entity in the biotechnology sector.
AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

30

CEO

Travis Murdoch, MD

Website

www.braveheart.bio

Headquarters

San Francisco, CA 94129, US

BRVE Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$2.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

70.65M

Volume

1.43K

Avg. Volume

1.65M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Braveheart Bio Performance Analysis

Braveheart Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20252025-12-31USD 0N/A
Braveheart Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20252025-12-31USD -0.93N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$2.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

30

N/A

Net Income

-$14.28

N/A

EBITDA

-$14.85

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$81.24

N/A

Total Debt

$0.67

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.29

N/A

Short Term Debt

$0.37

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$5.22

N/A

Operating Cash Flow

-$5.19

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,715.71-0.00%
^DJIDJI
$53,946.95-0.01%
^IXICNASDAQ
$26,362.59-0.00%
BTCBitcoin
$64,490.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
SPCXSpace Exploration Technologies
$114.92+0.06%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%

Questions About BRVE

What is the current price of Braveheart Bio?

Braveheart Bio is trading at $29.80 per share.

What is the 52-week range for Braveheart Bio?

Over the past 52 weeks, Braveheart Bio has traded between $18.00 and $31.56.

How much debt does Braveheart Bio have?

As of the most recent reporting period, Braveheart Bio reported total debt of $667.00K.

How much cash does Braveheart Bio have on hand?

Braveheart Bio reported $80.58M in cash and cash equivalents in its most recent financial results.

What is Braveheart Bio’s dividend yield?

Braveheart Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services